Zucali PA - Search Results

1

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis.

Anpalakhan S, Signori A, Cortellini A, Verzoni E, Giusti R, Aprile G, Ermacora P, Catino A, Pipitone S, Di Napoli M, Scotti V, Mazzoni F, Guglielmini PF, Veccia A, Maruzzo M, Schinzari G, Casadei C, Grossi F, Rizzo M, Montesarchio V, Verderame F, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Tondini CA, Camerini A, Banzi MC, Sorarù M, Zucali PA, Vignani F, Ricciardi S, Russo A, Cosenza A, Di Maio M, De Giorgi U, Pignata S, Giannarelli D, Pinto C, Buti S, Fornarini G, Rebuzzi SE, Rescigno P, Addeo A, Banna GL, Bersanelli M. Anpalakhan S, et al. Among authors: zucali pa. iScience. 2023 Sep 22;26(11):107970. doi: 10.1016/j.isci.2023.107970. eCollection 2023 Nov 17. iScience. 2023. PMID: 37860695 Free PMC article.

2

Biology and management of malignant pleural mesothelioma.

Zucali PA, Giaccone G. Zucali PA, et al. Eur J Cancer. 2006 Nov;42(16):2706-14. doi: 10.1016/j.ejca.2006.07.011. Epub 2006 Sep 20. Eur J Cancer. 2006. PMID: 16989994 Review.

3

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struys EA, Perrino M, Jansen G, Matherly LH, Peters GJ. Giovannetti E, et al. Among authors: zucali pa. Ann Oncol. 2017 Nov 1;28(11):2725-2732. doi: 10.1093/annonc/mdx499. Ann Oncol. 2017. PMID: 28945836 Free PMC article.

4

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, Roncalli M, Steinberg SM, Wang Y, Giaccone G. Petrini I, et al. Among authors: zucali pa. Cell Death Dis. 2012 Jul 19;3(7):e351. doi: 10.1038/cddis.2012.92. Cell Death Dis. 2012. PMID: 22825469 Free PMC article.

5

A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.

Giovannetti E, Leon LG, Gómez VE, Zucali PA, Minutolo F, Peters GJ. Giovannetti E, et al. Among authors: zucali pa. Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):643-651. doi: 10.1080/15257770.2016.1149193. Nucleosides Nucleotides Nucleic Acids. 2016. PMID: 27906635

6

Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?

Soto Parra HJ, Latteri F, Cavina R, De Vincenzo F, Zucali PA, Campagnoli E, Santoro A. Soto Parra HJ, et al. Among authors: zucali pa. J Am Geriatr Soc. 2005 Jun;53(6):1078-80. doi: 10.1111/j.1532-5415.2005.53338_6.x. J Am Geriatr Soc. 2005. PMID: 15935045 Clinical Trial. No abstract available.

7

Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen.

Magagnoli M, Masci G, Carnaghi C, Zucali PA, Castagna L, Morenghi E, Santoro A. Magagnoli M, et al. Among authors: zucali pa. Ann Oncol. 2003 Jun;14(6):959-60. doi: 10.1093/annonc/mdg238. Ann Oncol. 2003. PMID: 12796035 Free article. No abstract available.

8

"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma.

Giovannetti E, Peters GJ, Zucali PA. Giovannetti E, et al. Among authors: zucali pa. J Thorac Oncol. 2013 Aug;8(8):e79-80. doi: 10.1097/JTO.0b013e318293e45b. J Thorac Oncol. 2013. PMID: 23857408 Free article. No abstract available.

9

Timing of breast cancer surgery in relation to the menstrual cycle: an update of developments.

Zurrida S, Galimberti V, Gibelli B, Luini A, Gianoglio S, Sandri MT, Passerini R, Maisonneuve P, Zucali P, Jeronesi G, Pigatto F, Veronesi U. Zurrida S, et al. Crit Rev Oncol Hematol. 2001 Jun;38(3):223-30. doi: 10.1016/s1040-8428(00)00128-1. Crit Rev Oncol Hematol. 2001. PMID: 11369255 Review.

10

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.

Deutsch E, Moyal EC, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S. Deutsch E, et al. Among authors: zucali pa. Oncotarget. 2016 Dec 24;8(34):56199-56209. doi: 10.18632/oncotarget.14147. eCollection 2017 Aug 22. Oncotarget. 2016. PMID: 28915584 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page